Manufacturer | Source: Department of Pharmaceuticals
Published On: 04-05-2026
Enforcement Date: 04 May, 2026
Corrigendum/Addendum Dated 4.5.2026 in the Guidelines under PLI Scheme for Bulk Drugs
The Department of Pharmaceuticals has amended the PLI Scheme for Bulk Drugs guidelines, introducing provisions for partial incentive disbursement based on unaudited statements and extending the sales reconciliation deadline. Applicants can now receive 80% incentive disbursement initially, with the remaining amount released after audited submissions. The reconciliation timeline has also been extended from 31 December to 31 January.
The Department of Pharmaceuticals has notified amendments to the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs), Drug Intermediates, and Active Pharmaceutical Ingredients (APIs), commonly known as the PLI Scheme for Bulk Drugs.
Key points include:
- Based on decisions taken during the Empowered Committee meeting held on 12 March 2026, the revised guidelines introduce a new provision allowing applicants filing incentive claims using management-certified or unaudited financial statements to receive 80% of eligible incentives initially.
- The remaining 20% incentive will be disbursed after submission of audited financial statements, auditor certificates, and reconciliation with regulatory returns within ten months from the end of the financial year.
- Additionally, the deadline for reconciliation of sales documents has been extended from 31 December to 31 January of the subsequent financial year.
- All other provisions of the scheme remain unchanged.
Applicable For: Manufacturer
Reference Number: No. 31026/16/2020-Policy
Notification Link